Green Lane IRBs
Understand how SCRI supports Green Lane review pathways for industry-sponsored trials (ISTs) across public healthcare institutions (PHIs) in Singapore.
Enhancing Ethics Review for Industry-Sponsored Clinical Trials in Singapore
Supported through the Industry-Sponsored Trials Funding Initiative (IST-FI) under the Research, Innovation and Enterprise 2030 (RIE2030) initiative, SCRI supports Green Lane review pathways across Singapore's Public Healthcare Institutions (PHIs) for eligible industry-sponsored clinical trials.
Implemented by the two (2) Institutional Review Boards (IRBs), Green Lane reviews support streamlined review processes, enhanced submission readiness and dedicated review support while maintaining rigorous ethical, scientific and regulatory standards that safeguard research participants.
SingHealth Centralised Institutional Review Board (CIRB)
Enhanced ethics review pathway for eligible industry-sponsored studies, supporting efficient review processes while maintaining established ethical and regulatory standards.
Key features include:
Dedicated Green Lane review process
Twice-monthly Full Board meetings
Fast-tracked review timelines for complete and compliant submissions
Maintained ethical and regulatory review standards
Review timelines are targeted at approximately three (3) weeks from submission to outcome.
NHG Domain Specific Review Board (DSRB)
Provides end-to-end IRB support for eligible industry-sponsored clinical trials, supporting study teams throughout the review process and post-approval lifecycle while maintaining established ethical and regulatory standards.
Key features include:
Collaborative pre-submission support
Priority IRB review
Early engagement with reviewers
Guidance on documentation requirements for submission
Quality assurance review processes
Post-approval support throughout the study lifecycle, including amendments, renewals and safety event reporting